Original reporting and analysis on the stories shaping biotech.
Boehringer Ingelheim just handed LEO Pharma the keys to SPEVIGO, its first-in-class IL-36 blocker for a rare skin disease, in a €90 million deal. The logic behind selling an approved drug reveals where both companies think inflammation medicine is headed next.
Sarepta slapped the FDA's most serious safety warning on its Duchenne gene therapy while cutting 500 jobs in a single week. With Elevidys revenue down 75% from its peak and fatal liver cases in the rearview mirror, the gene therapy poster child is in full survival mode.
The 2026 Nobel Prize in Chemistry went to two scientists who figured out how to stop molecules from being made backwards. More than half of all drugs on the market depend on this kind of chemistry, and the implications for pharma are bigger than you think.
Ultragenyx just priced its new gene therapy Fayuvi at $3.95 million per patient, making it the second most expensive drug in the world. It's a one-time treatment for a fatal childhood brain disease with zero alternatives, and it's reigniting the fiercest debate in biotech: who pays for a genetic cure?
Eli Lilly's experimental obesity combo EloraTZP crushed its own blockbuster Zepbound in a head-to-head trial, with patients losing 23.3% of body weight versus 14.8%. It's a bold move that redefines the obesity drug arms race with Novo Nordisk.
The FDA just fast-tracked a review of what could be the first oral therapy for achondroplasia, the most common form of dwarfism. If BridgeBio's pill gets approved, it could upend a market where daily injections have been the only option for kids.
CSL just inked a deal worth up to $1.6 billion with a Swiss biotech most people have never heard of, all for a drug targeting a rogue protein in scarred organs. The science is elegant, the checks are enormous, and the clinical proof is still TBD.
The FDA is investigating patient deaths linked to Sarepta's Duchenne gene therapy Elevidys, pulling the emergency brake on one of biotech's highest-profile treatments. The fallout is raising hard questions about whether the most promising gene therapies are also the most dangerous.
Novartis just signed a deal worth up to $7.8 billion with a Chinese biotech most people have never heard of. The target isn't vaccines; it's an mRNA drug that turns your body into its own pharmaceutical factory for autoimmune disease.
Three scientists just won the Nobel Prize for figuring out how to control brain cells with light, a technique born from studying pond algae. The technology is already in late-stage clinical trials for blindness and reshaping how we understand Alzheimer's.
The FDA just opened a public comment period asking researchers, clinicians, and stakeholders to help design early-phase ibogaine clinical trials. It's an unusual move that signals growing regulatory seriousness about psychedelic medicine, even for a compound with known cardiac risks.
A Dutch VC firm just closed €2.3 billion for European biotech, the continent's largest life sciences fundraise ever. It's a massive vote of confidence in a market that desperately needs one, but the story underneath is more complicated than it looks.
No drug has ever been approved for the negative symptoms of schizophrenia. Click Therapeutics just got FDA clearance for a prescription smartphone app that did what pharma couldn't, and it could reshape how we think about treating serious mental illness.
Shionogi just agreed to pay $2 billion in cash for a tiny Texas biotech most people have never heard of. The reason? A first-in-class drug for two ultra-rare diseases and a pipeline that could reshape how we think about Japanese pharma's appetite for U.S. rare disease assets.
AbbVie and Genmab's epcoritamab just delivered a 51% reduction in disease progression when added to frontline chemo for the most common aggressive lymphoma. After 30 years of the same standard of care, the first-line DLBCL playbook may finally be getting a rewrite.
AstraZeneca dropped $2 billion on a 12% stake in Summit Therapeutics without licensing or acquiring its star cancer drug. The real play? A clinical collaboration that could define the next era of combination cancer therapy.
A two-year-old startup just inked its second massive deal, all centered on an organ most people forgot exists. Tolerance Bio's $560 million Tanabe pact is the latest sign that thymus biology could reshape how we treat autoimmune disease.
GE HealthCare is dropping $945 million on a company most people have never heard of, and the reason comes down to a brutal physics problem: radioactive drugs start dying the moment they're made. Here's why the "final mile" is suddenly worth a billion-dollar bet.
Sanofi and Regeneron were suing each other just last year. Now they've inked an $8 billion expansion of their immunology partnership, betting four next-generation antibodies can protect the franchise that Dupixent built. The real question: can this 20-year marriage survive the patent cliff?
Vaxcyte's VAX-31 just delivered Phase 3 data showing it can match Pfizer's and Merck's pneumococcal vaccines head-to-head, while covering 31 bacterial serotypes versus Pfizer's 20. The multibillion-dollar pneumococcal vaccine market may have a new contender that nobody saw coming.
Genentech just paid $100 million upfront (with up to $1.27 billion more on the table) for a preclinical Parkinson's program from Alector. The real prize isn't just the drug; it's a platform that tricks the brain into letting medicines past its toughest bouncer.
Enveda Biosciences just raised $311 million to turn nature's 3.8-billion-year chemical library into actual drugs, using AI to read what evolution wrote. The Series E round values the company at $2 billion, but the real test is whether its three clinical-stage candidates can survive rigorous trials.
Join thousands of biotech professionals who start their day with our free, daily briefing.